Immunotherapy in Advanced Melanoma: Changing the Treatment Paradigm
|
|
- Silvia Kelley
- 8 years ago
- Views:
Transcription
1 Immunotherapy in Advanced Melanoma: Changing the Treatment Paradigm
2 Learning Objectives Explain the importance of immunotherapy to the treatment of advanced melanoma and detail the mechanisms involved in the anti-ctla-4 and anti-pd-1 approaches Review the 2015 NCCN guidelines on the treatment of advanced melanoma, and in particular, recommendations regarding immunotherapy Select appropriate strategies for the management of patients with advanced melanoma based on both patient and therapeutic characteristics and side effect profiles 2 CTLA-4 = cytotoxic T-lymphocyte antigen-4; NCCN = National Comprehensive Cancer Network; PD-1 = programmed cell death-1.
3 2015 Estimated New Cancer Cases in the United States a Men 848,200 Women 810,170 Prostate 26% Lung and bronchus 14% Colon and rectum 8% Urinary bladder 7% Melanoma of skin 5% Non-Hodgkin lymphoma 5% Kidney 5% Oral cavity 4% Leukemia 4% Liver and bile duct 3% All other sites 19% Invasive melanoma: 73,870 Number of deaths from melanoma: patients/hour 29% Breast 13% Lung and bronchus 8% Colon and rectum 7% Uterine corpus 6% Thyroid 4% Non-Hodgkin lymphoma 4% Melanoma 3% Pancreas 3% Leukemia 3% Kidney 20% All other sites 3 a Excludes basal and squamous cell skin cancers and in situ carcinomas except urinary bladder. American Cancer Society. acspc pdf. Accessed June 5, 2015; National Cancer Institute. html/melan.html. Accessed June 8, 2015.
4 Melanoma: Increasing Incidence, Decreasing Mortality New melanoma cases nearly tripled between 1975 and 2012 (from 7.9/100K to 22.9/100K) Death rate per 100K: no change (2.1/100K in 1975; 2.7/100K in 2012) Historically, average survival for stage IV metastatic melanoma was 6-12 months; 5-year survival was under 10% with standard therapies 4 Deylon J, et al. Semin Oncol. 2015;42: ; National Cancer Institute. Accessed June 8, 2015.
5 Melanoma: An Epidemic Utah Incidence Rates of Melanoma of the Skin by State, 2011 Highest per capita incidence 34.1 / 100,000 73% higher than national average California 27.5 /100,000 40% higher than national average 8560 cases / year 5 Centers for Disease Control. Accessed June 5, 2015; Centers for Disease Control. Accessed June 5, 2015; AIM at Melanoma Foundation. about-melanoma-and-other-lesions/melanoma-stats-facts-and-figures. Accessed June 10, 2015.
6 Melanoma: 15-Year OS Proportion Surviving Stage I (n = 9175) Stage II (n = 5739) Stage III (n = 1528) Stage IV (n = 1158) Disease status at presentation 84% Localized 8% Regional metastases 4% Distant metastases Presence of lymph node metastasis most important prognostic factor for survival 6 OS = overall survival. Survival (years) Balch CM, et al. J Clin Oncol. 2001;19: ; Siegel J, et al. CA Cancer J Clin. 2012;61:10-29.
7 Case 1: Frank 71-year-old married, retired construction worker ~6 months ago, he noticed a dark irregular mole on the sole of his foot that was uncomfortable and ulcerating, but he put off coming in because of fears about what it might be When he showed his wife, she insisted that he see his doctor Symptoms include right abdominal swelling and fatigue Frank has T2DM of 17 years duration, hypertension, and moderate chronic kidney disease Medications include metformin, an angiotensin-converting enzyme inhibitor, and a diuretic 7 T2DM = type 2 diabetes mellitus.
8 Case 1 (cont d) Physical examination BP: 131/84 mm Hg; heart rate: 86 beats/min, regular; temperature: 97.8ºF (36.5ºC); RR: 14 breaths/min BMI: 29.5 kg/m 2 ; A1C is 7.2%; GFR: 40 ml/min/1.73 m 2 Right plantar foot: irregular, large pigmented lesion Large palpable lymph nodes in the right groin Results of the rest of the examination are within normal limits A punch biopsy of the mole is performed 3.8-mm ulcerated acral lentiginous melanoma: T3b Fine-needle cytology aspiration of right groin lymph nodes Metastatic melanoma Image courtesy of Robert Andtbacka, MD, CM 8 A1C = glycated hemoglobin; BMI = body mass index; BP = blood pressure; GFR = glomerular filtration rate; RR = respiration rate.
9 Case 1 (cont d) Imaging: chest/abdominal/pelvic CT scan and brain MRI Multiple enlarged metastatic lymph nodes in the right superficial and deep groin Liver lesions with significant peritumoral edema compatible with metastases Multiple lung metastases Final stage pt3b, N3, M1c stage IV with liver and lung metastases Serum LDH: 1838 U/L (normal <264 U/L) Lymph node metastasis: BRAF V600 wild type 9 CT = computed tomography; LDH = lactic dehydrogenase; MRI = magnetic resonance imaging.
10 History of Melanoma Treatment DTIC IL Dacarbazine FDA approved in 1975 ORRs 5%-10%, poor prognosis High-dose IL-2 approved in 1998 ORR 15% Higher response in patients with disease limited to skin and/or lymph nodes 10 DTIC = dacarbazine; FDA = Food and Drug Administration; IL-2 = interleukin-2; ORR = overall response rate. Buzaid AC, et al. Chin Clin Oncol. 2014;3:32; Buzaid AC, et al. Accessed June 5, 2015; Chapman PB, et al. N Engl J Med. 2011;364: ; Hauschild A, et al. Lancet. 2012;380:
11 New Paradigm in the Treatment of Melanoma Immunotherapy Target host Targeted therapy Target tumor 11 Courtesy of Axel Hauschild, MD.
12 History of Melanoma Treatment (cont d) DTIC IL-2 Ipilimumab Vemurafenib Dabrafenib alone Trametinib alone Ipilimumab FDA approved in 2011 Improvement in OS in metastatic disease Vemurafenib approved 2011 for BRAF V600E-mutant disease Dabrafenib and trametinib approved in 2013 (monotherapy) Approved in combination (for BRAF V600E-mutant disease) in Buzaid AC, et al. Chin Clin Oncol. 2014;3:32.
13 Immune System Checkpoint Inhibitors Anti-CTLA-4 agents Ipilimumab Binds to CTLA-4, blocking its ability to downregulate T-cell activation, proliferation, and effector function Anti-PD-1 and PD-L1 agents Pembrolizumab Nivolumab PD-1 pathway is a key immuno-inhibitory mediator of T-cell exhaustion; blockade of pathway leads to T-cell activation, expansion, and enhanced effector functions PD-1 = programmed cell death-1; PD-L1 = programmed death-ligand National Cancer Institute. Accessed June 5, 2015; Yervoy [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; 2015; Keytruda [prescribing information]. Whitehouse Station, NJ: Merck & Co., Inc.; 2015; Opdivo [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; 2015.
14 Ipilimumab Augments T-Cell Activation and Proliferation T-Cell Activation T-Cell Inhibition T-Cell Activation and Proliferation CTLA-4 T cell T cell T cell TCR MHC APC CD28 CD80/ CD86 TCR MHC APC CD28 CTLA-4 CD80/ CD86 TCR MHC APC CD80/ CD86 CTLA-4 Ipilimumab blocks CTLA-4 APC = antigen-presenting cells; MHC = major histocompatibility complex; TCR = T-cell receptor. 14 O Day S, et al. ASCO 2010 Annual Meeting; June 4-8, 2010; Chicago, IL. Abstract 4.
15 Clinical Results With Ipilimumab (Second and First Line) Ipilimumab vs Vaccine and Ipilimumab + DTIC vs DTIC HR: 0.66 and Patients who were pretreated with Ipi 3 mg/kg ± gp100 HR: First-line Ipi 10 mg/kg + DTIC 15 gp100 = glycoprotein 100; HR = hazard ratio; Ipi = ipilimumab. 1. Hodi FS, et al. N Engl J Med. 2010;363: ; 2. Robert C, et al. N Engl J Med. 2011;364:
16 History of Melanoma Treatment (cont d) DTIC IL-2 Ipilimumab Pembrolizumab Nivolumab Vemurafenib Dabrafenib combined with trametinib Dabrafenib alone Trametinib alone Pembrolizumab and nivolumab approved in Buzaid AC, et al. Chin Clin Oncol. 2014;3:32.
17 Role of PD-1 Pathway in Suppressing Anti-Tumor Immunity 17 PD 1 receptor blocking antibody and PD L1/2 receptor blocking antibody CD28 = cluster of differentiation 28; IFN = interferon; NFκB = nuclear factor-kappa B; PI3K = phosphatidylinositol-3 kinase; Shp-2 = Src homology protein tyrosine phosphatase-2. Sznol M. ASCO 2013 Annual Meeting; May 31-June 4, 2013; Chicago, IL. Abstract CRA9006.
18 Pembrolizumab vs Chemotherapy in Progressive Disease Following Ipilimumab Therapy, Primary End Point: Progression-Free Survival Progression Free Survival, % Arm Pembro 2 Q3W Pembro 10 Q3W Chemotherapy Median (95% CI), mo 2.9 ( ) 2.9 ( ) 2.7 ( ) Time, months Rate at 6 mo Rate at 9 mo Mean, a mo 34% 24% % 29% 5.8 HR (95% CI) 0.57 ( ) 0.50 ( ) P <.0001 < % 8% Q3W = every 3 weeks. Adapted from Ribas A, et al. Society of Melanoma Research Congress 2014; November 18-21, 2014; San Francisco, CA. Abstract.
19 Pembrolizumab Dose-Comparison Study in Ipilimumab-Refractory Advanced Melanoma RECIST Criteria; Independent Central Review Pembrolizumab 2 mg/kg (n = 81) Pembrolizumab 10 mg/kg (n = 76) ORR, % (95% CI) 26 (17-37) 26 (17-38) Best Overall Response (%) CR 1 1 PR SD PD Unable to determine 16 9 DCR (95% CI) 51 (39-62) 50 (38-62) 19 CR = complete response; DCR = disease control rate; PD = progressive disease; PR = partial response; RECIST = response evaluation criteria in solid tumors; SD = stable disease. Robert C, et al. Lancet. 2014;384:
20 Nivolumab vs Standard Chemotherapy With Dacarbazine in Treatment-Naïve Patients With Unresectable Stage III or IV Melanoma: Primary End Point OS Follow-up since randomization: months. 20 Robert C, et al. N Engl J Med. 2015;372:
21 Nivolumab vs Standard Chemotherapy With Dacarbazine in Treatment-Naïve Patients With Unresectable Stage III or IV Melanoma Nivolumab (N = 210) Dacarbazine (N = 208) ORR, % (95% CI) 40 (33-47) 14 (10-19) Best Overall Response (%) CR 8 1 PR SD PD Unable to determine Robert C, et al. N Engl J Med. 2015;372:
22 Blocking CTLA-4 and PD-1 22 Wolchok JD, et al. ASCO 2013 Annual Meeting; May 31-June 4, 2013; Chicago, IL. Abstract 9012.
23 Nivolumab + Ipilimumab Study Best change from baseline in target lesion volume (Median) Nivolumab alone % Nivolumab + ipilimumab % Ipilimumab alone + 5.9% 23 Larkin J et al. N Engl J Med DOI: /NEJMoa
24 Nivolumab + Ipilimumab Combination Therapy Demonstrates High Response Rate Therapy ORR (%) Response Odds Ratio compared to ipilimumab (95% CI) Ipilimumab 19.0% Nivolumab alone 43.7% 3.40 ( ) Nivolumab + ipilimumab 57.6% 6.11 ( ) 24 Larkin J, et al. N Engl J Med May 31. [Epub ahead of print].
25 Nivolumab + Ipilimumab Combination Therapy Demonstrates Improvement in Progression-Free Survival 25 Larkin J, et al. N Engl J Med May 31. [Epub ahead of print].
26 Nivolumab Plus Ipilimumab Combination Therapy: Treatment-related Adverse Events Nivolumab alone (N=313) Any Grade % Grade 3/4 % Nivolumab + ipilimumab (N=313) Any Grade % Grade 3/4 % Ipilimumab alone (N=311) Any Grade % Grade 3/4 % All drug-related adverse events Skin Gastrointestinal Hepatic Endocrine 14 < Pulmonary 2 < <1 26 Larkin J, et al. N Engl J Med May 31. [Epub ahead of print].
27 Antitumoral Response: Targeted Therapies vs Immunotherapies a Tumor Response a CTLA-4 antibodies, PD-1 antibodies, and combined CTLA-4 and PD-1 antibodies. 27 Hauschild A, et al. ASCO 2014 Annual Meeting; May 30-June 3, 2014; Chicago, IL. Abstract 9013.
28 According to NCCN guidelines, Frank is not a candidate for IL-2 therapy due to:?decision POINT 1. Elevated LDH 2. Comorbid T2DM 3. Inadequate organ reserve 4. Comorbid hypertension Use your keypad to vote now! 28
29 Among melanoma metastases, a worse prognosis is associated with:?key QUESTION 1. Nodal metastases 2. Liver metastases 3. Pulmonary metastases 4. Brain metastases Use your keypad to vote now! 29
30 How would you treat Frank??DECISION POINT 1. Dacarbazine 2. High-dose IL-2 3. BRAF inhibitor 4. Anti-CTLA-4 (ipilimumab) 5. Anti-PD-1 (pembrolizumab or nivolumab) Use your keypad to vote now! 30
31 Treatment of Advanced Melanoma in a Patient With Liver and Lung Metastases, T2DM, and Moderate Kidney Disease Dacarbazine: not appropriate 1 High-dose IL-2: not appropriate for compromised renal function 2 BRAF inhibitor not appropriate in patients with BRAF wild-type 3 Ipilimumab: FDA-approved for first line, but low response NCCN guidelines recommend anti-pd-1 agents (pembrolizumab and nivolumab) as first-line therapy due to higher response rates and less toxicity than ipilimumab 5 Pembrolizumab and nivolumab are not FDA-approved as first-line treatments National Comprehensive Care Network. Accessed June 5, 2015; 2. Robert C, et al. N Engl J Med. 2015;372: ; 3. Long GV, et al. Society of Melanoma Research Congress 2014; November 13-17; 2014; Zurich, Switzerland; 4. Ribas A, et al. Society of Melanoma Research Congress 2014; November 13-17; 2014; Zurich, Switzerland; 5. Zelboraf [prescribing information]. South San Francisco, CA: Genentech, Inc.; 2014.
32 Case (cont d) Frank is given pembrolizumab, 200 mg intravenously every 3 weeks After the first treatment, he is assessed by his healthcare provider and is found to be experiencing grade 2 fatigue and constipation He is advised to set priorities, pace himself, establish good sleep hygiene, and join an exercise class at a local cancer center to improve his energy levels He is given bisacodyl 10 mg 3 times daily, with the goal of achieving 1 nonforced bowel movement every 1-2 days National Comprehensive Care Network. Accessed June 5, 2015; 2. National Comprehensive Care Network. Accessed June 8, 2015; 3. NCCN 2015 Palliative Care Guidelines. pdf/palliative.pdf. Accessed June 5, 2015.
33 AE Profile of Immune Checkpoint Therapies Any Grade AE Ipilimumab (%) Immune Checkpoint Therapy Pembrolizumab (%) Nivolumab (%) Diarrhea (diarrhea or Colitis 8 1 colitis) Pruritus Rash Fatigue Constipation Yervoy [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; 2015; Keytruda [prescribing information]. Whitehouse Station, NJ: Merck, Inc.; 2015; Opdivo [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; 2015; Revicki DA, et al. Health Qual Life Outcomes. 2012;10:66; Weber JS, et al. Lancet Oncol. 2015;16:
34 Immune-Related AEs: Ipilimumab vs Pembrolizumab Toxicity Ipilimumab (n = 1498) % Pembrolizumab (n = 411) % All Grades Grade 3/4 All Grades Grade 3/4 GI (eg, colitis) <1 Pneumonitis <1 <1 2.9 <1 Hepatitis <1 <1 Dermatologic Hypophysitis <1 <1 Thyroiditis 1.8 <1 9.5 <1 Nephritis <1 <1 <1 <1 34 Teply BA, Lipson EJ. Oncology. 2014;28(suppl 3):30-38.
35 Assessment for Treatment AEs Assess the patient for AEs associated with immunotherapy, including: Dermatologic effects GI effects Hepatic effects Endocrine effects Renal effects Uveitis Pneumonitis 35
36 Management of AEs of Immunotherapy: An Example Ipilimumab: Immune-Mediated Dermatitis Determine Severity of Dermatitis Moderate Severe or life threatening Management Withhold ipilimumab If no improvement within 1 week, administer topical or systemic corticosteroids Permanently discontinue ipilimumab Administer systemic corticosteroids 1-2 mg/kg/d prednisone equivalent Follow-up/Symptoms Resolved Resume ipilimumab if dermatitis resolves or improves to mild and systemic steroid dose is 7.5 mg prednisone equivalent or less When dermatitis is controlled, taper corticosteroid over at least 1 month 36 Yervoy [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; 2015.
37 Case 2: Jeanine Jeanine is a 54-year-old married school teacher with 2 college-aged children About a month ago, her husband noticed a dark mole on the outside of her left thigh that appeared to have grown; she made an appointment to come in for a visit Jeanine is healthy, exercises regularly, and maintains a good body weight; she has no comorbidities, and other than having seasonal allergies, is in excellent health BP: 115/70 mm Hg; heart rate: 72 beats/min, regular; temperature: 98.1 F (36.7 C); RR: 15 breaths/min BMI: 23.2 kg/m 2 Medication: vitamins 37
38 Case 2 (cont d) On examination 2.5-cm-diameter multicolored, irregular border, slightly exophytic pigmented lesion No lymphadenopathy An excisional biopsy of the mole is performed 1.8-mm Breslow thickness Image courtesy of Robert Andtbacka, MD, CM Clarks level IV Ulcerated Superficial spreading melanoma Recommendation for wide local excision and sentinel lymph node biopsy No evidence of residual melanoma in wide local excision No evidence of lymph node metastasis Stage pt2b, N0, M0, stage IIA 38
39 How would you treat Jeanine??DECISION POINT 1. Observation or clinical trial 2. IFN 3. Anti-CTLA-4 (ipilimumab) 4. Anti-PD-1 (pembrolizumab or nivolumab) Use your keypad to vote now! 39
40 NCCN Recommendation for Follow-up for Stage IIA Melanoma Adjuvant clinical trial or observation History and physical examination (with emphasis on nodes and skin) every 6-12 months for 5 years, then annual skin exams Routine radiologic imaging to screen for asymptomatic recurrent/metastatic disease is not recommended 40 National Comprehensive Cancer Network. pdf/melanoma.pdf. Accessed June 8, 2015.
41 Case 2: Jeanine If, there was a 4 mm micrometastatic disease deposit in 1 of 3 sentinel lymph nodes Recommendation for staging work-up: A chest/abdominal/pelvic CT scan and brain MRI show no evidence of metastatic lesions LDH 156 U/L (normal < 264 U/L) A left groin completion lymph node dissection showed no evidence of metastatic disease in an additional 10 lymph nodes Final stage pt2b, N1a, M0, stage IIIB 41
42 How would you treat Jeanine, who has stage IIIB disease??decision POINT 1. Observation or clinical trial or IFNα 2. Standard of care anti- CTLA-4 (ipilimumab) 3. Standard of care anti- PD-1 (pembrolizumab or nivolumab) Use your keypad to vote now! 42
43 NCCN 2015 Guidelines The NCCN 2015 Guideline recommendations for Stage III (sentinel node positive) disease are: o Clinical trial or observation or interferon alfa Stage III (clinically positive node[s]) are: o Clinical trial or observation or interferon alfa and/or RT (radiotherapy) to nodal basin in select patients based on location, size, and number of involved nodes, and or macroscopic extranodal extension 43 NCCN 2015 Melanoma Guidelines.
44 Interferon alpha Mechanism of action First described in 1957 by Isaacs and Lindenman Interferes with viral replication > IFN IFNα (2a and 2b) Antitumor effects Activates natural killer cells Antiproliferative Antiangiogenic Upregulation of HLA I and II antigen presentation 44 Tarhini AA, et al. J Immunol. 2012;189:
45 ECOG 1684: Overall Survival Extent of Disease Patients N = 280 pt4, N0 31 (11%) LN micromets 34 (12%) LN macromets 41 (15%) LN recurrence 174 (62%) Over 70% had macrometastatic disease in lymph nodes No. No. Median 5-Year Patients Dead (years) P Value Survival (%) 45 IFN -2b Observation LN = lymph node. Kirkwood JE, et al. J Clin Oncol. 1996;14:7-17.
46 ECOG 1684 First nonsurgical randomized trial in advanced melanoma to show an OS advantage Led to FDA approval of high-dose IFN Became standard of care in United States in 1995 (entering 19th year) 46 Kirkwood JE, et al. J Clin Oncol. 1996;14:7-17.
47 Meta-Analyses of All IFN Trials Confirm RFS, OS Impact Meta-Analysis No. of RCTs RFS OS Comment Wheatley Cancer Treat Rev Wheatley ASCO ± 13 + OR = 0.87; 95% CI, ; P = OR = 0.9; 95% CI = ; P =.008 Did not include E1694 benefit with IFN dose RFS 13% risk reduction; 10% risk reduction in OS Mocellin JNCI HR = 0.82; 95% CI, ; P < HR = 0.89; 95% CI, ; P =.002 RFS 18% risk reduction OS 11% risk reduction 47 OR = odds ratio; RCT = randomized control trial; RFS = relapse-free survival. Tarhini AA, et al. J Immunol. 2012;189:
48 Adjuvant IFN vs Biochemotherapy: S-0008 Treatment Schema Induction IFN: 20 MIU/m 2 IV; Monday-Friday; week 1-4 Maintenance IFN: 10 MIU/m 2 SC; Monday, Wednesday, and Friday; weeks 5-52 Weeks Cisplatin 20 mg/m 2 IV days 1-4 Vinblastine 1.2 mg/m 2 IV days 1-4 DTIC 800 mg/m 2 IV day 1 IL-2 9 MIU/m 2 CIV days 1-4 IFN 5 MIU/m 2 SC days 1-4 IFN 5 MIU SC days 8, 10, 12 G-CSF 5ug/kg SC days 7-16 No treatment 48 CIV = continuous IV; G-CSF = granulocyte-colony stimulating factor; IV = intravenous; SC = subcutaneous.
49 S-0008: Relapse-Free Survival 5 year RFS BCT 48% HDI 39% Median RFS BCT 4.0 years HDI 1.9 years 49 BCT = biochemotherapy; HDI = high-dose IFN. Flaherty LE, et al. J Clin Oncol. 2014;32:
50 S-0008: Overall Survival 5 year OS BCT 56% HDI 56% Median OS BCT 9.9 years HDI 6.7 years 50 Flaherty LE, et al. J Clin Oncol. 2014;32:
51 EORTC Ipilimumab vs Placebo in Resected Stage III Melanoma Randomization (IIIA, IIIB, IIIC except in-transit) N = 950 Ipilimumab 10 mg/kg Placebo Primary end point: RFS 51 Eggermont AM, et al. ASCO 2014 Annual Meeting; May 30-June 3, 2014; Chicago, IL. Abstract LBA9008.
52 Primary End Point: RFS Independent Review Committee Ipilimumab Placebo 100 Events/patients 234/ / HR (95% CI) a 0.75 ( ) 90 Log-rank P value Year RFS rate (%) *Stratified by stage Year RFS rate (%) b Median: 26.1 mo **Data are not yet mature. 60 Median: 26.1 months Median: 17.1 mo 40 Median: 17.1 months Ipilimumab Ipilimumab mg/kg mg/kg Placebo Placebo Patients at Risk Months O O N N Ipilimumab Placebo Patients Alive Without Relapse (%) 52 a Stratified by stage; b Data are not yet mature. Eggermont AM, et al. ASCO 2014 Annual Meeting; May 30-June 3, 2014; Chicago, IL. Abstract LBA9008.
53 MK-3475 (pembrolizumab) vs IFN for Resected High-Risk Melanoma a A Phase 3 Randomized Study 1:1 53 a SWOG 1404 Intergroup. AJCC = American Joint Committee on Cancer.
54 Case (cont d) Jeanine choses observation NCCN 2015 guidelines recommend: History and physical examination (with emphasis on nodes and skin) every 3-6 months for 2 years, then every 3-12 months for 3 years, then annually Consider chest x-ray, CT, and/or PET/CT scans every 3-12 months to screen for recurrent/metastatic disease, and an annual brain MRI for stage IIB through IV Routine radiologic imaging to screen for asymptomatic recurrent/metastatic disease is not recommended after 3-5 years 54 PET = positron-emission tomography.
55 Recap: NCCN 2015 Guidelines on Surveillance Patients with melanoma stages IA-IIA should be assessed by physical examination of skin and lymph nodes every 6-12 months for 5 years Patients with melanoma stages IIB-IV should be assessed every 3-6 months for 2 years by physical examination of skin and lymph nodes and every 3-12 months for 3 years, then annually as clinically indicated Chest x-ray, CT, and/or PET/CT scans every 3-12 months to screen for recurrent/metastatic disease Consider annual brain MRI 55
56 Assessment for Disease Progression Patients with early-stage melanoma should undergo physical examination of skin and lymph nodes every 6-12 months for 5 years Patients with later-stage disease should receive both regular physical examination of skin and lymph nodes and imaging every 3-12 months; annual brain MRI should be considered 56
57 Assessment for Disease Progression Patients with more advanced disease should be advised of the existence of ongoing clinical trials for which they may qualify 57
58 Examples of Clinical Trials in Patients With Advanced Melanoma Oncolytic virus (T-VEC) in combination with ipilimumab Oncolytic virus (T-VEC) in combination with pembrolizumab Pembrolizumab in combination with trametinib and dabrafenib (KEYNOTE-022) T-VEC = talimogene laherparepvec. 58 NIH. Accessed June 8, 2015; NIH. PEMBROLIZUMAB+AND+TALIMOGENE&rank=1. Accessed June 8, 2015; NIH. AND+MELANOMA&rank=7. Accessed June 8, 2015.
59 T-VEC + Ipilimumab Phase 1b Trial ( ) S C R E E N I N G E N R O L L M E N T Screening 28 days prior to enrollment Stage IIIB/C-IV M1c melanoma not suitable for surgical resection, no prior systemic treatment (except adjuvant treatment) T-VEC up to 4 ml 10 6 pfu/ml week 1 day 1, 10 8 pfu/ml week 4, day 1 and then every 2 weeks + Ipilimumab 3 mg/kg every 3 weeks x 4 starting week 6, day 1 N = 19 T-VEC dosing until CR, all injectable tumors disappeared, PD per immune-related response criteria, or intolerance for treatment, whichever comes first E N D O F T R E A T M E N T S A F E T Y F O L L O W - U P 30 (+7) days after last dose of T-VEC or 60 (+7) days after last dose of ipilimumab S U R V I V A L F O L L O W - U P Up to 24 months after end of randomization Primary end point: Incidence of dose-limiting toxicities Secondary end points: ORR, safety: all AEs, grade 3 AEs, serious AEs, events requiring discontinuation of study drug, events with local effects on tumors (pain, inflammation, and ulceration) 59 Puzanov I, et al. ASCO 2014 Annual Meeting. May 30-June 3, 2014; Chicago, IL. Abstract 9029; NIH. Accessed June 8, 2015.
60 Maximal Change in Tumor Burden With T-VEC and Ipilimumab Percentage Change From Baseline Patients (N = 17) a Investigator-Assessed Responses N = 18 b Overall response 10 (56%) (95% CI, 31%-79%) CR 6 (33%) PR 4 (22%) SD 3 (17%) PD 5 (28%) Stage IIIb (N = 1) Stage IIIc (N = 3) Stage IV M1a (N = 4) Stage IV M1b (N = 5) Stage IV M1c (N = 4) 60 a One patient assessed to have PD by the investigator was not shown in the plot because tumor burden could not be accurately calculated based on missing post-baseline data. b Efficacy analysis set includes only patients who received both T-VEC and ipilimumab. Puzanov I, et al. ASCO 2014 Annual Meeting; May 30-June 3, 2014; Chicago, IL. Abstract 9029.
61 PCE ACTION PLAN
62 PCE Action Plan Counsel patients/caregivers on the importance of anticipating and treating AEs of treatment to avoid interruption of effective therapy Counsel patients/caregivers on the importance of regular follow-ups Counsel patients/caregivers on the possibility of enrolling in a clinical trial PCE Promotes Practice Change 62
Anti-PD1 Agents: Immunotherapy agents in the treatment of metastatic melanoma. Claire Vines, 2016 Pharm.D. Candidate
+ Anti-PD1 Agents: Immunotherapy agents in the treatment of metastatic melanoma Claire Vines, 2016 Pharm.D. Candidate + Disclosure I have no conflicts of interest to disclose. + Objectives Summarize NCCN
More informationCancer Treatments Subcommittee of PTAC Meeting held 18 September 2015. (minutes for web publishing)
Cancer Treatments Subcommittee of PTAC Meeting held 18 September 2015 (minutes for web publishing) Cancer Treatments Subcommittee minutes are published in accordance with the Terms of Reference for the
More informationCombination Immunotherapies: Melanoma
Combination Immunotherapies: Melanoma Igor Puzanov, MD, MSCI, FACP Associate Professor of Medicine, Associate Director of Phase I Drug Development, Director, Melanoma Research, Clinical Director, Renal
More informationCLINICAL POLICY Department: Medical Management Document Name: Opdivo Reference Number: CP.PHAR.121 Effective Date: 07/15
Page: 1 of 6 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted
More informationTrials in Elderly Melanoma Patients (with a focus on immunotherapy)
Trials in Elderly Melanoma Patients (with a focus on immunotherapy) Where we were Immunotherapy Trials: past and present Relevance for real world practice Where we are SIOG October 2012 James Larkin FRCP
More informationMelanoma and Immunotherapy
Melanoma and Immunotherapy Sanjiv S. Agarwala, MD Professor of Medicine Temple University School of Medicine Chief, Oncology & Hematology St. Luke s Cancer Center, Bethlehem, PA The Transformed Landscape
More informationNEW CLINICAL RESEARCH OPTIONS IN PANCREATIC CANCER IMMUNOTHERAPY. Alan Melcher Professor of Clinical Oncology and Biotherapy Leeds
NEW CLINICAL RESEARCH OPTIONS IN PANCREATIC CANCER IMMUNOTHERAPY Alan Melcher Professor of Clinical Oncology and Biotherapy Leeds CANCER IMMUNOTHERAPY - Breakthrough of the Year in Science magazine 2013.
More informationCurrent Status of Immunotherapy For the Treatment of Metastatic Melanoma
Current Status of Immunotherapy For the Treatment of Metastatic Melanoma The 2016 Arizona Clinical Oncology Society Meeting Richard W. Joseph, MD Assistant Professor Mayo Clinic Florida joseph.richard@mayo.edu
More informationOvarian Cancer and Modern Immunotherapy: Regulatory Strategies for Drug Development
Ovarian Cancer and Modern Immunotherapy: Regulatory Strategies for Drug Development Sanjeeve Bala, MD, MPH Ovarian Cancer Endpoints Workshop FDA White Oak September 3, 2015 Overview Immune agents from
More informationImmunotherapy for High-Risk and Metastatic Melanoma
Immunotherapy for High-Risk and Metastatic Melanoma Timothy M. Kuzel, MD Professor of Medicine and Dermatology Feinberg School of Medicine Northwestern University Chicago ICLIO 1 st Annual National Conference
More informationFoundational Issues Related to Immunotherapy and Melanoma
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationCheckMate -057, a Pivotal III Opdivo (nivolumab) Lung Cancer Trial, Stopped Early
April 21, 2015 CheckMate -057, a Pivotal III Opdivo (nivolumab) Lung Cancer Trial, Stopped Early Opdivo Demonstrates Superior Overall Survival Compared to Docetaxel in Patients with Previously-Treated
More informationComparing Immunotherapy with High Dose IL-2 and Ipilimumab
Comparing Immunotherapy with High Dose IL-2 and Ipilimumab Michael K Wong MD PhD FRCPC mike.wong@med.usc.edu Disclosures Speaker s Bureau, Advisory Boards, Consultant: Prometheus Bristol Myers Squibb Novartis
More information10 th EADO Congress Vilnius, 7-10 May 2014. Ipilimumab update. Michele Maio
10 th EADO Congress Vilnius, 7-10 May 2014 Ipilimumab update Michele Maio Medical Oncology and Immunotherapy, Department of Oncology University Hospital of Siena, Istituto Toscano Tumori SIENA, ITALY Evolving
More informationAttached from the following page is the press release made by BMS for your information.
July 22, 2015 CheckMate -025 (global clinical trial), a Pivotal Phase III Opdivo (nivolumab) Renal Cancer Trial Stopped Early (PRINCETON, NJ, July 20, 2015) Bristol-Myers Squibb Company (NYSE:BMY) announced
More informationMedia Contacts: Annick Robinson Investor Contacts: Teri Loxam (438) 837-2550 (908) 740-1986
News Release Media Contacts: Annick Robinson Investor Contacts: Teri Loxam (438) 837-2550 (908) 740-1986 Merck Announces Initial Results for Pembrolizumab with Novel Immunotherapy Combinations from Three
More informationWhat is the Optimal Front-Line Treatment for mrcc? Michael B. Atkins, MD Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center
What is the Optimal Front-Line Treatment for mrcc? Michael B. Atkins, MD Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center The Case for Immunotherapy in mrcc 1. Achieves patient s goal 2.
More informationOncos Therapeutics: ONCOS THERAPEUTICS Personalized Cancer Immunotherapy. March 2015. Antti Vuolanto, COO and co-founder
Oncos Therapeutics: Personalized Cancer Immunotherapy ONCOS THERAPEUTICS Personalized Cancer Immunotherapy March 2015 Antti Vuolanto, COO and co-founder 1 History of Oncos Therapeutics 2002 2007 2009 Research
More informationCurrent Clinical Trials Soft Tissue and Skin Metastases
Current Clinical Trials Soft Tissue and Skin Metastases Sanjiv S. Agarwala, MD Professor of Medicine, Temple University Chief, Oncology & Hematology St. Luke s Cancer Center Bethlehem, PA, USA Soft Tissue/Skin
More information18.5 Percent Overall Response Rate Observed in Pembrolizumab-Treated Patients with this Aggressive Form of Breast Cancer
News Release Media Contacts: Annick Robinson Investor Contacts: Joseph Romanelli (514) 837-2550 (908) 740-1986 Stephanie Lyttle NATIONAL Public Relations (514) 843-2365 Justin Holko (908) 740-1879 Merck
More informationIMMUNOTHERAPY FOR THE TREATMENT OF LUNG CANCER
IMMUNOTHERAPY FOR THE TREATMENT OF LUNG CANCER BOOKLET SUPPLEMENT Immunotherapy Immunotherapy is one of the most exciting new approaches for treating several types of cancer, including lung cancer. Immunotherapies
More informationTKCC/Garvan Cancer Biology Seminars Melanoma & Cancer Immunotherapy
TKCC/Garvan Cancer Biology Seminars Melanoma & Cancer Immunotherapy 19/02/2016 A/Prof Anthony Joshua Head, Dept of Medical Oncology St Vincent s Hospital, Sydney Immunotherapy Progress: A Long Time Coming
More informationImmunotherapy Concept Turned Reality
Authored by: Jennifer Dolan Fox, PhD VirtualScopics Inc. jennifer_fox@virtualscopics.com +1 585 249 6231 Immunotherapy Concept Turned Reality Introduction While using the body s own immune system as a
More informationASCO 12. PD-1 Immunotherapy Makes a Splash at ASCO
PD-1 Immunotherapy Makes a Splash at ASCO By Gregory R. Wolfe, PhD Epigenetic variation and genetic instability in tumor cells yield a variety of tumor antigens that the immune system can recognize to
More informationBackground. t 1/2 of 3.7 4.7 days allows once-daily dosing (1.5 mg) with consistent serum concentration 2,3 No interaction with CYP3A4 inhibitors 4
Abstract No. 4501 Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a Phase III randomized, open-label, multicenter trial R. Motzer, D.
More informationOncologist-to-Oncologist: How to Treat Your Patients with Immunotherapy
Oncologist-to-Oncologist: How to Treat Your Patients with Immunotherapy Michael A. Postow, M.D. Memorial Sloan Kettering Cancer Center Wednesday, June 10, 2015 11:00 a.m. EDT Brought to you by the Cancer
More informationTargeted Therapy What the Surgeon Needs to Know
Targeted Therapy What the Surgeon Needs to Know AATS Focus in Thoracic Surgery 2014 David R. Jones, M.D. Professor & Chief, Thoracic Surgery Memorial Sloan Kettering Cancer Center I have no disclosures
More informationImmunotherapy or Molecularly Targeted Therapy: What Is the Best Initial Treatment for Stage IV BRAF-Mutant Melanoma?
Immunotherapy or Molecularly Targeted Therapy: What Is the Best Initial Treatment for Stage IV BRAF-Mutant Melanoma? Geoffrey T. Gibney, MD, and Michael B. Atkins, MD Geoffrey T. Gibney, MD, is an attending
More informationBADO meeting. Immunotherapy. in Metastatic Melanoma
BADO meeting Immunotherapy in Metastatic Melanoma UCL Université catholique de Louvain Prof J-Fr. BAURAIN Medical Oncology Department BADO Meeting Inaugural Lecture 07 december 2013 Melanoma Treatment
More informationYour Immune System & Melanoma Treatment
Your Immune System & Melanoma Treatment Immunotherapy and Melanoma Immunotherapy is rapidly emerging as an important approach to treating many forms of cancer. For people with melanoma, the news is particularly
More informationImmunotherapy for Metastatic Renal Cell Carcinoma
Immunotherapy for Metastatic Renal Cell Carcinoma Timothy M. Kuzel, MD Professor of Medicine and Dermatology Feinberg School of Medicine Northwestern University Chicago, Ilinois ICLIO 1 st Annual National
More informationThe Past, Present & Future of Cancer Immunotherapy:
Article The Past, Present & Future of Cancer Immunotherapy: An Overview Recently BioWorld called cancer immunotherapy white hot based on unprecedented investments in private companies, partnerships between
More informationMaintenance therapy in in Metastatic NSCLC. Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai
Maintenance therapy in in Metastatic NSCLC Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai Definition of Maintenance therapy The U.S. National Cancer Institute s
More informationTreating Melanoma S kin Cancer A Quick Guide
Treating Melanoma Skin Cancer A Quick Guide Contents This is a brief summary of the information on Treating melanoma skin cancer from our website. You will find more detailed information on the website.
More informationWhat You Need to Know About Lung Cancer Immunotherapy
What You Need to Know About Lung Cancer Immunotherapy Lung.org/immunotherapy What is immunotherapy? Immunotherapy for cancer, sometimes called immune-oncology, is a type of medicine that treats cancer
More informationGUIDELINES FOR THE MANAGEMENT OF LUNG CANCER
GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER BY Ali Shamseddine, MD (Coordinator); as04@aub.edu.lb Fady Geara, MD Bassem Shabb, MD Ghassan Jamaleddine, MD CLINICAL PRACTICE GUIDELINES FOR THE TREATMENT
More informationKidney Cancer OVERVIEW
Kidney Cancer OVERVIEW Kidney cancer is the third most common genitourinary cancer in adults. There are approximately 54,000 new cancer cases each year in the United States, and the incidence of kidney
More informationKanıt: Klinik çalışmalarda ZYTIGA
mkdpk de Sonunda Gerçek İlerleme! Kanıt: Klinik çalışmalarda ZYTIGA Dr. Sevil Bavbek 5. Türk Tıbbi Onkoloji Kongresi Mart 214, Antalya Endocrine therapies Adrenals Testis Abiraterone Orteronel Androgen
More informationPredictive Biomarkers for PD1 Pathway Inhibitor Immunotherapy
Predictive Biomarkers for PD1 Pathway Inhibitor Immunotherapy Michael B. Atkins, M.D. Deputy Director Georgetown-Lombardi Comprehensive Cancer Center Michael Atkins, MD Consulting Fees (e.g., advisory
More informationCoxsackievirus A21 (CAVATAK TM ) - mediated oncolytic immunotherapy in advanced melanoma patients
Coxsackievirus A21 (CAVATAK TM ) - mediated oncolytic immunotherapy in advanced melanoma patients Robert H.I. Andtbacka 1, Brendan Curti 2, Mark Grose 3, Len Post 4, Jeffrey Ira Weisberg 4 and Darren Shafren
More informationNew Treatment Options for Breast Cancer
New Treatment Options for Breast Cancer Brandon Vakiner, PharmD., BCOP Clinical Pharmacy Specialist - Oncology The University of Iowa Hospitals and Clinics Assistant Professor (Clinical) University of
More informationImmuno-Oncology Therapies to Treat Lung Cancer
Immuno-Oncology Therapies to Treat Lung Cancer What you need to know ONCHQ14NP07519 Introduction: Immuno-oncology represents an innovative approach to cancer research that seeks to harness the body s own
More informationPreliminary Results from a Phase 2 Study of ARQ 197 in Patients with Microphthalmia Transcription Factor Family (MiT) Associated Tumors
Preliminary Results from a Phase 2 Study of ARQ 197 in Patients with Microphthalmia Transcription Factor Family (MiT) Associated Tumors John Goldberg 1 *, George Demetri 2, Edwin Choy 3, Lee Rosen 4, Alberto
More informationMetastatic Breast Cancer 201. Carolyn B. Hendricks, MD October 29, 2011
Metastatic Breast Cancer 201 Carolyn B. Hendricks, MD October 29, 2011 Overview Is rebiopsy necessary at the time of recurrence or progression of disease? How dose a very aggressive treatment upfront compare
More informationA912: Kidney, Renal cell carcinoma
A912: Kidney, Renal cell carcinoma General facts of kidney cancer Renal cell carcinoma, a form of kidney cancer that involves cancerous changes in the cells of the renal tubule, is the most common type
More informationJanuary 2013 LONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Summary. Contents
LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Paclitaxel albumin (Abraxane ) as a substitute for docetaxel/paclitaxel for cancer Paclitaxel albumin (Abraxane ) as a substitute for docetaxel/ paclitaxel for
More information7. Prostate cancer in PSA relapse
7. Prostate cancer in PSA relapse A patient with prostate cancer in PSA relapse is one who, having received a primary treatment with intent to cure, has a raised PSA (prostate-specific antigen) level defined
More informationRESEARCH EDUCATE ADVOCATE. Just Diagnosed with Melanoma Now What?
RESEARCH EDUCATE ADVOCATE Just Diagnosed with Melanoma Now What? INTRODUCTION If you are reading this, you have undergone a biopsy (either of a skin lesion or a lymph node) or have had other tests in which
More informationBefore, Frank's immune cells could
Before, Frank's immune cells could barely recognize a prostate cancer cell. Now, they are focused on it. Stimulate an immune response against advanced prostate cancer Extend median survival beyond 2 years
More informationAdditional 50 patients enrolled in KEYNOTE-001 with analyses planned using Merck s proprietary PD-L1 assay at one percent and 50 percent cut points
News Release Media Contacts: Annick Robinson Dominique Quirion Merck NATIONAL Annick.robinson@merck.com dquirion@national.ca 514 428-2890 514 843-2302 Investor Contacts: Justin Holko: (+1 908-423-5088
More informationMALIGNANT LYMPHOMAS. Dr. Olga Vujovic (Updated August 2010)
MALIGNANT LYMPHOMAS Dr. Olga Vujovic (Updated August 2010) Malignant lymphomas consist of Hodgkin and non-hodgkin lymphomas. The current management of these diseases involves a multi-disciplinary approach.
More informationRotation Specific Goals & Objectives: University Health Network-Princess Margaret Hospital/ Sunnybrook Breast/Melanoma
Rotation Specific Goals & Objectives: University Health Network-Princess Margaret Hospital/ Sunnybrook Breast/Melanoma Medical Expert: Breast Rotation Specific Competencies/Objectives 1.0 Medical History
More informationYour Immune System & Lung Cancer Treatment
Your Immune System & Lung Cancer Treatment Immunotherapy and Lung Cancer Immunotherapy is quickly developing as an important approach to treating many forms of cancer, including lung cancer. Immunotherapy
More informationImmunoteràpia en el Limfoma de Hodgkin
Immunoteràpia en el Limfoma de Hodgkin A. Sureda Servei d Hematologia Institut Català d Oncologia - Hospitalet SCHH. Barcelona, 22 de juny de 2016 OS from relapse after an ASCT. The experience of the LWP
More informationEverolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer
LONDON CANCER NEWS DRUGS GROUP RAPID REVIEW Everolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer Everolimus plus exemestane for second-line
More informationUnderstanding series. new. directions. 1-800-298-2436 LungCancerAlliance.org. A guide for the patient
Understanding series LUNG CANCER: new treatment directions 1-800-298-2436 LungCancerAlliance.org A guide for the patient TABLE OF CONTENTS What s New in lung cancer? Advancements...4 Changes in genes that
More informationGUSTAVE ROUSSY AT ASCO
GUSTAVE ROUSSY AT ASCO PRESS RELEASE 30 MAY 03 JUNE MELANOMA www.gustaveroussy.fr/asco 30 MAY 03 JUNE 14 GUSTAVE ROUSSY AT ASCO PRESS RELEASE ASCO MAY 30 th - JUNE 3 rd 50 th congress American Society
More informationImmuno-Oncology, The New Era of Cancer Treatment. Ted Lee, MD, MPH Disease Area Head, IO, Pac Rim, Bristol Myers Squibb
Immuno-Oncology, The New Era of Cancer Treatment Ted Lee, MD, MPH Disease Area Head, IO, Pac Rim, Bristol Myers Squibb 1 Disclosures Dr. Ted Lee is an employee of Bristol-Myers Squibb Co. New Therapies
More informationPathologic Assessment Of The Breast And Axilla After Preoperative Therapy
Pathologic Assessment Of The Breast And Axilla After Preoperative Therapy W. Fraser Symmans, M.D. Associate Professor of Pathology UT M.D. Anderson Cancer Center Pathologic Complete Response (pcr) Proof
More informationThe Di Bella Method (DBM) improves Survival, Objective Response and Performance Status in Breast Cancer
BIT's 4th World Cancer Congress 2011 People s Republic of China Dalian The Di Bella Method (DBM) improves Survival, Objective Response and Performance Status in treated with DBM therapy Retrospective observational
More informationIMMUNOMEDICS, INC. February 2016. Advanced Antibody-Based Therapeutics. Oncology Autoimmune Diseases
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases February 2016 Forward-Looking Statements This presentation, in addition to historical information, contains certain
More informationSmall Cell Lung Cancer
Small Cell Lung Cancer Types of Lung Cancer Non-small cell carcinoma (NSCC) (87%) Adenocarcinoma (38%) Squamous cell (20%) Large cell (5%) Small cell carcinoma (13%) Small cell lung cancer is virtually
More informationNew Targets and Treatments for Follicular Lymphoma. Disclosures
Winship Cancer Institute of Emory University New Targets and Treatments for Follicular Lymphoma Jonathon B. Cohen, MD, MS Assistant Professor Div of BMT, Emory University Disclosures Consulting fees from:
More informationThis regimen has low emetogenic potential refer to local protocol None required routinely. Baseline results valid for 7 days. Results valid for 72 hrs
Regimen : Ipilimumab for Advanced Melanoma ICD10 code Codes pre-fixed with C43. Indication Regimen detail Ipilimumab is recommended as an option for treating advanced (unresectable or metastatic) melanoma
More informationNew and Emerging Immunotherapies for Multiple Sclerosis: Oral Agents
New and Emerging Immunotherapies for Multiple Sclerosis: Oral Agents William Tyor, M.D. Chief, Neurology Atlanta VA Medical Center Professor, Department of Neurology Emory University School of Medicine
More informationImmuno-Oncology 2015: A New Landscape in Lung Cancer
Immuno-Oncology 2015: A New Landscape in Lung Cancer David R. Spigel, M.D. Lung Cancer Program Director Sarah Cannon Research Institute/Tennessee Oncology, PLLC Nashville, TN Off-Label Use Disclosure(s)
More informationAdvances and perspectives in immunotherapy of melanoma
Annals of Oncology 23 (Supplement 10): x104 x108, 2012 doi:10.1093/annonc/mds321 Advances and perspectives in immunotherapy of melanoma D. Schadendorf*, J. Vaubel, E. Livingstone & L. Zimmer Department
More informationIntegrating Chemotherapy and Liver Surgery for the Management of Colorectal Metastases
I Congresso de Oncologia D Or July 5-6, 2013 Integrating Chemotherapy and Liver Surgery for the Management of Colorectal Metastases Michael A. Choti, MD, MBA, FACS Department of Surgery Johns Hopkins University
More informationDisclosures. Disclosures. Grand Unification: The rationale for combining immunotherapy and molecular targeted therapy 25/02/2014
Grand Unification: The rationale for combining immunotherapy and molecular targeted therapy Ryan J. Sullivan, M.D. Massachusetts General Hospital / Harvard University Canadian Melanoma Conference February
More informationROLE OF RADIATION THERAPY FOR RESECTABLE LUNG CANCER
AFA 08958 From Bench to Bedside From KK DT1 10/27/2015 12:04 PM 01 ROLE OF RADIATION THERAPY FOR RESECTABLE LUNG CANCER Hak Choy, MD University of Texas Southwestern Medical Center Dallas, Texas, USA Orchestrating
More informationMetastatic Melanoma What You Need to Know
ESSENTIALS Metastatic Melanoma Metastatic Melanoma What You Need to Know If you have metastatic melanoma, you may feel as though your life has been turned upside down. It s a serious disease, but patients
More informationBreast Cancer Treatment Guidelines
Breast Cancer Treatment Guidelines DCIS Stage 0 TisN0M0 Tamoxifen for 5 years for patients with ER positive tumors treated with: -Breast conservative therapy (lumpectomy) and radiation therapy -Excision
More informationFalse positive PET in lymphoma
False positive PET in lymphoma Thomas Krause Introduction and conclusion 2 3 Introduction 4 FDG-PET in staging of lymphoma 34 studies with 2227 Patients CT FDG-PET Sensitivity 63 % 89 % (58%-100%) (63%-100%)
More informationVan Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.
Efficacy Results from the ToGA Trial: A Phase III Study of Trastuzumab Added to Standard Chemotherapy in First-Line HER2- Positive Advanced Gastric Cancer Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.
More informationCancer Treatments Subcommittee of PTAC Meeting held 2 March 2012. (minutes for web publishing)
Cancer Treatments Subcommittee of PTAC Meeting held 2 March 2012 (minutes for web publishing) Cancer Treatments Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology
More informationAdvances In Chemotherapy For Hormone Refractory Prostate Cancer. TAX 327 study results & SWOG 99-16 study results presented at ASCO 2004
Ronald de Wit Rotterdam Cancer Institute The Netherlands Advances In Chemotherapy For Hormone Refractory Prostate Cancer TAX 327 study results & SWOG 99-16 study results presented at Slide 1 Prostate Cancer
More informationCANCER PULMON: ESTADIOS INICIALES POSTMUNDIAL PULMON DENVER 2015. 8-10-2015.Manuel Cobo Dols S. Oncología Médica HU Málaga Regional y VV
CANCER PULMON: ESTADIOS INICIALES POSTMUNDIAL PULMON DENVER 2015 8-10-2015.Manuel Cobo Dols S. Oncología Médica HU Málaga Regional y VV Meta-analisis LACE: adyuvancia vs no adyuvancia Pignon JP, et al.
More informationAdvances in immunotherapy for melanoma
Redman et al. BMC Medicine (2016) 14:20 DOI 10.1186/s12916-016-0571-0 MINIREVIEW Open Access Advances in immunotherapy for melanoma Jason M. Redman 1,2, Geoffrey T. Gibney 1,2 and Michael B. Atkins 1,2*
More informationCarcinoma of the vagina is a relatively uncommon disease, affecting only about 2,000 women in
EVERYONE S GUIDE FOR CANCER THERAPY Malin Dollinger, MD, Ernest H. Rosenbaum, MD, Margaret Tempero, MD, and Sean Mulvihill, MD 4 th Edition, 2001 Vagina Jeffrey L. Stern, MD Carcinoma of the vagina is
More informationIMMUNOTHERAPY OF MELANOMA Anti PD1 Takes Center Stage. Dr Peter Hersey Professor of Melanoma Biology University of Sydney
IMMUNOTHERAPY OF MELANOMA Anti PD1 Takes Center Stage Dr Peter Hersey Professor of Melanoma Biology University of Sydney What we have learnt about immunotherapy over the past 3 years Inhibition of Physiologic
More informationTOXIC EFFECTS OF CHEMOTHERAPY, IMMUNOTHERAPY AND CHEMOIMMUNOTHERAPY IN PATIENTS WITH CUTANEOUS MELANOMA
2014 TOXIC EFFECTS OF CHEMOTHERAPY, IMMUNOTHERAPY AND CHEMOIMMUNOTHERAPY IN PATIENTS WITH CUTANEOUS MELANOMA * Oradea University, Faculty of Medicine and Pharmacy, 10 Decembrie 1 St St., Oradea, Romania,
More informationAnticancer Immunotherapy A New Weapon Against Cancer JON STEPHENS, MPHIL SENIOR ANALYST, ONCOLOGY
Anticancer Immunotherapy A New Weapon Against Cancer JON STEPHENS, MPHIL SENIOR ANALYST, ONCOLOGY A robust new approach Since its inception in the mid-0th century, chemotherapy has been the mainstay of
More informationHow To Treat A Uterine Sarcoma
EVERYONE S GUIDE FOR CANCER THERAPY Malin Dollinger, MD, Ernest H. Rosenbaum, MD, Margaret Tempero, MD, and Sean Mulvihill, MD 4 th Edition 2001 Uterus: Uterine Sarcomas Jeffrey L. Stern, MD Uterine sarcomas
More informationCHAPTER 2. Neoplasms (C00-D49) March 2014. 2014 MVP Health Care, Inc.
Neoplasms (C00-D49) March 2014 2014 MVP Health Care, Inc. CHAPTER SPECIFIC CATEGORY CODE BLOCKS C00-C14 Malignant neoplasms of lip, oral cavity and pharynx C15-C26 Malignant neoplasms of digestive organs
More informationU.S. Food and Drug Administration
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA s website for reference purposes only. It was current when produced, but is no longer maintained
More informationManagement of low grade glioma s: update on recent trials
Management of low grade glioma s: update on recent trials M.J. van den Bent The Brain Tumor Center at Erasmus MC Cancer Center Rotterdam, the Netherlands Low grades Female, born 1976 1 st seizure 2005,
More informationGeneral Rules SEER Summary Stage 2000. Objectives. What is Staging? 5/8/2014
General Rules SEER Summary Stage 2000 Linda Mulvihill Public Health Advisor NCRA Annual Meeting May 2014 National Center for Chronic Disease Prevention and Health Promotion Division of Cancer Prevention
More informationAvastin in breast cancer: Summary of clinical data
Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading
More informationAvastin: Glossary of key terms
Avastin: Glossary of key terms Adenocarcinoma Adenoma Adjuvant therapy Angiogenesis Anti-angiogenics Antibody Antigen Avastin (bevacizumab) Benign A form of carcinoma that originates in glandular tissue.
More informationDiagnosis and Prognosis of Pancreatic Cancer
Main Page Risk Factors Reducing Your Risk Screening Symptoms Diagnosis Treatment Overview Chemotherapy Radiation Therapy Surgical Procedures Lifestyle Changes Managing Side Effects Talking to Your Doctor
More informationBrigham and Women s Hospital, Boston, MA, USA; 2 Verastem, Inc., Boston, MA, USA
Determination of Biomarker Response in a Phase II Window of Opportunity Study of Defactinib (VS 6063), a Focal Adhesion Kinase (FAK) Inhibitor, in Patients with Resectable Malignant Pleural Mesothelioma
More informationUs TOO University Presents: Understanding Diagnostic Testing
Us TOO University Presents: Understanding Diagnostic Testing for Prostate Cancer Patients Today s speaker is Manish Bhandari, MD Program moderator is Pam Barrett, Us TOO International Made possible by
More information亞 東 紀 念 醫 院 Follicular Lymphoma 臨 床 指 引
前 言 : 惡 性 淋 巴 瘤 ( 或 簡 稱 淋 巴 癌 ) 乃 由 體 內 淋 巴 系 統 包 括 淋 巴 細 胞 淋 巴 管 淋 巴 腺 及 一 些 淋 巴 器 官 或 組 織 如 脾 臟 胸 腺 及 扁 桃 腺 等 所 長 出 的 惡 性 腫 瘤 依 腫 瘤 病 理 組 織 型 態 的 不 同 可 分 為 何 杰 金 氏 淋 巴 瘤 (Hodgkin s disease) 與 非 何 杰 金
More informationReport series: General cancer information
Fighting cancer with information Report series: General cancer information Eastern Cancer Registration and Information Centre ECRIC report series: General cancer information Cancer is a general term for
More informationLUNG CANCER TREATMENTS. What you need to know about... immunotherapy
LUNG CANCER TREATMENTS What you need to know about... immunotherapy foreword About LUNGevity LUNGevity is the largest national lung cancer-focused nonprofit, changing outcomes for people with lung cancer
More informationMelanoma: assessment and management of melanoma
Melanoma: assessment and management of melanoma NICE guideline Draft for consultation, January 2015 If you wish to comment on this version of the guideline, please be aware that all the supporting information
More informationBREAST CANCER UPDATE C H R I S S Z Y A R T O, D O G E N E S E E H E M A T O L O G Y O N C O L O G Y F L I N T, M I
BREAST CANCER UPDATE C H R I S S Z Y A R T O, D O G E N E S E E H E M A T O L O G Y O N C O L O G Y F L I N T, M I Overview Why is it important to understand breast cancer? Choosing wisely Appropriateness
More informationSmoking and misuse of certain pain medicines can affect the risk of developing renal cell cancer.
Renal cell cancer Renal cell cancer is a disease in which malignant (cancer) cells form in tubules of the kidney. Renal cell cancer (also called kidney cancer or renal adenocarcinoma) is a disease in which
More informationMOLOGEN AG. Q1 Results 2015 Conference Call Dr. Matthias Schroff Chief Executive Officer. Berlin, 12 May 2015
Q1 Results 2015 Conference Call Dr. Matthias Schroff Chief Executive Officer Berlin, 12 May 2015 V1-6 Disclaimer Certain statements in this presentation contain formulations or terms referring to the future
More informationSMALL CELL LUNG CANCER
Protocol for Planning and Treatment The process to be followed in the management of: SMALL CELL LUNG CANCER Patient information given at each stage following agreed information pathway 1. DIAGNOSIS New
More information